Oxynorm (Oxycodone Hydrochloride)

Oxycodone Hydrochloride, the active ingredient in Oxynorm, is an opioid analgesic presented as a strength/form for oral use. It is used to treat moderate to severe pain in adult patients when other analgesics are insufficient. GNH USA supplies Oxynorm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oxynorm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxynorm is an opioid analgesic that acts on the central nervous system to manage pain.

- Acute postoperative pain: provides rapid relief of pain following surgery. - Cancer‑related pain: helps control persistent pain associated with malignant disease. - Severe chronic non‑cancer pain: reduces ongoing pain when other treatments are inadequate.

Oxynorm may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Nausea and vomiting - Constipation - Drowsiness or sedation - Dry mouth - Sweating - Dizziness

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Seizures - Allergic reactions such as rash or anaphylaxis - Dependence, tolerance and withdrawal syndrome - Opioid‑induced adrenal insufficiency

When prescribing Oxynorm, clinicians should consider several safety measures.

- Assess pain severity and prior opioid use: ensure appropriate indication. - Evaluate respiratory function: monitor for depression, especially after dose changes. - Review concomitant CNS depressants: adjust dosing or increase monitoring. - Screen for substance‑use disorder: consider risk‑mitigation strategies. - Use the lowest effective dose: aim for the minimum dose that provides analgesia. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Oxynorm can interact with a variety of medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with strong‑acting ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - MAO‑inhibitors: risk of severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - Benzodiazepines or other sedatives: increased risk of respiratory depression. - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise oxycodone plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce analgesic effect. - Antidepressants (SSRIs, SNRIs): potential for additive CNS depression. - Antihistamines: may enhance sedation and dizziness.